**Specifications Table**Subject Area:*Chemistry*More specific subject area:*Medicinal Chemistry*Protocol name:*A practical synthesis of a novel DPAGT1 Inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB) for in vivo studies*Reagents/tools:*All were operated with standard tools available in general synthetic and biochemistry lab.*Experimental design:All synthetic steps were demonstrated in gram-quantity. Selectivity of all asymmetric reactions is greater than 15:1 ratio.Trial registration:*N/A*Ethics:*N/A*

**Value of the Protocol**•All reactions were performed in over one gram-scale; the desired product was synthesized \>1.0 g quantity.•Synthesis of a novel DPAGT1 inhibitor•Physicochemical property of a therapeutically interesting DPAGT1 inhibitor is summarized.

Description of protocol {#se0155}
=======================

Synthesis of a novel DPAGT1 inhibitor, aminouridyl phenoxypiperidinbenzyl butanamide (APPB, 1) {#sec0005}
----------------------------------------------------------------------------------------------

The monomethoxytetrachlorodiphenylmethoxymethyl (MTPM)-protected uridine **2** was prepared according to the previously reported procedure \[[@bib0005]\]. The *primary* alcohol of **2** was oxidized by a modified Swern condition to provide the corresponding aldehyde in quantitative yield, which was then subjected to Carreira's asymmetric alkynation reaction using (−)-*N*-methylephedrine \[[@bib0010]\], yielding the (*S*)-propargyl alcohol **3** in 80% yield with selectivity of \>98:2. NIS-AgBF~4~ promoted ribosylation of (*S*)-propargyl alcohol **3** with **4** furnished the β-riboside **5** exclusively in 95% yield. The azido group of **5** was reduced with Zn metal in the presence of aq. NH~4~Cl, and the triple bond was partially reduced with Lindlar's catalyst. The generated free-amine was protected with (Boc)~2~O to furnish **6** in 64% overall yield. The alkene moiety of **6** was subjected to a two-step procedure (osmylation and oxidative cleavage with Pb(OAc)~4~), providing the crude aldehyde **7**. Ti(O^i^Pr)~4~-mediated Strecker reaction of **7** with the 4-aminobutanamide derivatives **8** provided the *S*-diasteromer **9*S*** in 70% yield with greater than 15:1 *S*/*R* ratio. The desired diastereomer, **9*S*** was subjected to hydration reaction with HgCl~2~-acetoaldoxime, furnishing the amide **10** in 83% overall yield. Global deprotection of **10** was performed in one-pot two step reaction using 30% TFA in CH~2~Cl~2~ followed by 80% TFA in H~2~O; the crude product was purified by DOWEX 50W x 4 ion exchange resin followed by preparative HPLC to furnish **1** in 88% overall yield ([Scheme 1](#fig0005){ref-type="fig"}).Scheme 1Synthesis of APPB **(1)**.Scheme 1

### General {#sec0010}

All chemicals were purchased from commercial sources and used without further puriﬁcation unless otherwise noted. THF, CH~2~Cl~2~, and DMF were purified *via* Innovative Technology\'s Pure-Solve System. All reactions were performed under nitrogen atmosphere. Reactions were monitored by TLC using 0.25 mm coated commercial silica gel plates (EMD, Silica Gel 60F~254~). TLC spots were visualized by UV light at 254 nm, or developed with ceric ammonium molybdate or anisaldehyde or copper sulfate or ninhydrin solutions by heating on a hot plate. Reactions were also monitored by using SHIMADZU LCMS-2020 with solvents: A: 0.1% formic acid in water, B: acetonitrile. Flash chromatography was performed with SiliCycle silica gel (Purasil 60 Å, 230--400 Mesh). ^1^H NMR spectral data were recorded on 400, and 500 MHz instruments. ^13^C NMR spectral data were recorded on 100 and 125 MHz instruments. For all NMR spectra, chemical shifts (δH, δC) were quoted in parts per million (ppm), and *J* values were quoted in Hz. ^1^H and ^13^C NMR spectra were calibrated with residual undeuterated solvent (CDCl~3~: δH = 7.26 ppm, δC = 77.16 ppm; CD~3~CN: δH = 1.94 ppm, δC = 1.32 ppm; CD~3~OD: δH = 3.31 ppm, δC = 49.00 ppm; DMSO-d~6~: δH = 2.50 ppm, δC = 39.52 ppm; D~2~O: δH = 4.79 ppm) as an internal reference. The following abbreviations were used to designate the multiplicities: s = singlet, d = doublet, dd = double doublets, t = triplet, q = quartet, quin = quintet, hept = heptet, m = multiplet, br = broad. Infrared (IR) spectra were recorded on a Perkin-Elmer FT1600 spectrometer. HPLC analyses were performed with a Shimadzu LC-20AD HPLC system. HR-MS data were obtained from a Waters Synapt G2-Si (ion mobility mass spectrometer with nanoelectrospray ionization).

### Synthetic procedure for **1** {#sec0015}

**3,3-Dimethylpentane-1,5-diol (16)**: The title compound was synthesized according to the reported procedure \[[@bib0005],[@bib0015]\]: TLC (hexanes/EtOAc 20:80) *R~f~* = 0.20; IR (thin film) ν~max~ = 3317 (br), 2955, 2934, 1676, 1469, 1366, 1030, 1006, 990 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 3.73 (t, *J* = 7.0 Hz, 4H), 2.04 (brs, 2H), 1.57 (t, *J* = 7.0 Hz, 4H), 0.94 (s, 6H); ^13^C NMR (101 MHz, CDCl~3~) δ 59.60 (2C), 44.06 (2C), 31.67, 28.08 (2C); HRMS (ESI+) *m*/*z* calcd for C~7~H~16~O~2~ 132.1150, found 132.1144.

**5-Hydroxy-3,3-dimethylpentyl acetate (17)**: To a stirred solution of **16** (47.5 g, 359.3 mmol) in CH~2~Cl~2~ (500 mL) were added pyridine (31.8 mL, 395.2 mmol), Ac~2~O (33.9 mL, 359.3 mmol) and DMAP (0.44 g, 3.59 mmol) at 0 °C. The reaction mixture was stirred for 12 h at rt, and all volatiles were evaporated *in vacuo*. Purification by silica gel column chromatography (hexanes/EtOAc 90:10 to 50:50) to gave **17** (26.3 g, 150.9 mmol, 42%): TLC (hexanes/EtOAc 67:33) *R~f~* = 0.20; ^1^H NMR (400 MHz, Chloroform-*d*) δ 4.13 (t, *J* = 7.5 Hz, 2H), 3.72 (t, *J* = 7.5 Hz, 2H), 2.04 (s, 3H), 1.57 (dt, *J* = 14.8, 7.5 Hz, 4H), 0.95 (s, 6H); HRMS (ESI+) *m*/*z* calcd for C~9~H~18~O~3~ 174.1256, found 174.1249.

**3,3-Dimethyl-5-((triisopropylsilyl)oxy)pentyl acetate (18)**: To a stirred solution of **17** (26.3 g, 150.9 mmol) and imidazole (20.6 g, 301.8 mmol) in dry CH~2~Cl~2~ (500 mL) were added TIPSCl (48.4 mL, 226.4 mmol) and DMAP (0.18 g, 1.51 mmol) at 0 °C. The reaction mixture was warmed to rt and stirred for 16 h. The reaction was quenched with saturated NaHCO~3~ (aq.) and extracted with CH~2~Cl~2~. The combined organic extracts were dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 97:3) to obtain **18** (49.4 g, 149.4 mmol, 99%): TLC (hexanes/EtOAc 90:10) *R~f~* = 0.70; ^1^H NMR (400 MHz, Chloroform-*d*) δ 4.12 (t, *J* = 7.6 Hz, 2H), 3.74 (t, *J* = 7.2 Hz, 2H), 2.03 (s, 3H), 1.59 (t, *J* = 7.6 Hz, 2H), 1.53 (t, *J* = 7.2 Hz, 2H), 1.11--1.02 (m, 21H), 0.94 (s, 6H); HRMS (ESI+) *m*/*z* calcd for C~18~H~39~O~3~Si \[M+H\] 331.2668, found 331.2685.

**3,3-Dimethyl-5-((triisopropylsilyl)oxy)pentan-1-ol (19)**: To a stirred solution of **18** (49.4 g, 149.4 mmol) in MeOH/THF (4:1, 300 mL) was added \[*^t^*Bu~2~Sn(OH)Cl\]~2~ (0.86 g, 1.50 mmol). After 20 h at rt, all volatiles were evaporated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 95:5 to 90:10) to provide **19** (38.8 g, 134.5 mmol, 90%): TLC (hexanes/EtOAc 80:20) *R~f~* = 0.40; IR (thin film) ν~max~ = 3343 (br), 2941, 2891, 2866, 1463, 1384, 1366, 1096, 1065, 1012, 995, 881, 745, 678, 656 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 3.76 (t, *J* = 6.9 Hz, 2H), 3.72 (t, *J* = 7.2 Hz, 2H), 1.57 (td, *J* = 7.1, 2.8 Hz, 4H), 1.12--1.03 (m, 21H), 0.94 (s, 6H); ^13^C NMR (101 MHz, CDCl~3~) δ 60.30, 59.85, 44.31, 31.67, 28.14 (2C), 18.05 (6C), 11.95 (3C); HRMS (ESI+) *m*/*z* calcd for C~16~H~36~O~2~Si 288.2485, found 288.2473.

**3,3-Dimethyl-5-((triisopropylsilyl)oxy)pentanoic acid (15)**: To a stirred solution of **19** (38.8 g, 134.5 mmol) and TEMPO (1.05 g, 6.73 mmol) in MeCN (135 mL) an phosphate buffer (pH = 6.8, 135 mL) were added NaClO~2~ (14.6 g, 141.4 mmol) and bleach (8.25%, 65 mL) at 35 °C. After being stirred for 4 h, the reaction mixture was extracted with EtOAc and combined organic phase was dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 90:10) to give **15** (40.7 g, 134.5 mmol, 100%) as an orange oil: TLC (hexanes/EtOAc 50:50) *R~f~* = 0.50; IR (thin film) ν~max~ = 2942, 2866, 1705, 1463, 1246, 1097, 996, 881, 738, 678 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 3.88 (t, *J* = 5.8 Hz, 2H), 2.38 (s, 2H), 1.71 (t, *J* = 5.8 Hz, 2H), 1.20--1.11 (m, 3H), 1.09 (s, 12H), 1.08 (s, 6H), 1.07 (s, 6H); ^13^C NMR (101 MHz, CDCl~3~) δ 173. 9, 60.7, 46.8, 42.6, 32.4, 28.5 (2C), 17.9 (6C), 11.8 (3C); HRMS (ESI+) *m*/*z* calcd for C~16~H~34~O~3~NaSi \[M+Na\] 325.2175, found 325.2171.

**(2*R*,3*S*,4*S*,5*S*)-2-(Acetoxymethyl)-5-(*p*-tolylthio)tetrahydrofuran-3,4-diyl diacetate (10)**: The title compound was synthesized according to the reported procedure \[[@bib0005]\]: TLC (hexanes/EtOAc 50:50) *R~f~* = 0.60; \[α\]^20^~D~ −0.411 (*c* = 0.51, CHCl~3~); IR (thin film) ν~max~ = 1742, 1371, 1214, 1091, 1045, 1017, 899, 810 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.41 (d, *J* = 8.1 Hz, 2H), 7.14 (d, *J* = 7.7 Hz, 2H), 5.25--5.22 (m, 1H), 5.21--5.17 (m, 2H), 4.26--4.20 (m, 2H), 4.07 (dd, *J* = 12.9, 5.5 Hz, 1H), 2.34 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 170.50, 169.63, 169.42, 138.80, 134.18 (2C), 129.81 (2C), 127.45, 87.95, 79.97, 73.67, 71.41, 63.46, 21.15, 20.75, 20.53 (2C); HRMS (ESI+) *m*/*z* calcd for C~18~H~22~O~7~NaS \[M+Na\] 405.0984, found: 405.0970.

**(2*R*,3*S*,4*S*,5*S*)-2-(Hydroxymethyl)-5-(*p*-tolylthio)tetrahydrofuran-3,4-diyl diacetate (12)**: To a stirred solution of **10** (24.3 g, 62.8 mmol) in MeOH/THF (4:1, 300 mL) was added \[*^t^*Bu~2~Sn(OH)Cl\]~2~ (0.72 g, 1.26 mmol). After 20 h at rt, all volatiles were evaporated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 67:33) to provide **11** (17.9 g, 52.7 mmol, 83%): TLC (hexanes/EtOAc 60:40) *R~f~* = 0.40; \[α\]^21^~D~ −0.298 (*c* = 1.37, CHCl~3~); IR (thin film) ν~max~ = 3484 (br), 3021, 2924, 2877, 1746, 1493, 1432, 1373, 1239, 1222, 1102, 1093, 1046, 1017, 810 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.43 (d, *J* = 7.8 Hz, 2H), 7.16 (d, *J* = 7.8 Hz, 2H), 5.27 (d, *J* = 5.6 Hz, 1H), 5.24 (t, *J* = 4.6 Hz, 1H), 5.20 (d, *J* = 5.8 Hz, 1H), 4.13 (q, *J* = 3.7 Hz, 1H), 3.74 (dd, *J* = 12.3, 2.8 Hz, 1H), 3.58 (dd, *J* = 12.2, 3.2 Hz, 1H), 2.34 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 169.89, 169.39, 138.92, 133.88 (2C), 129.93 (2C), 127.45, 87.76, 83.46, 73.89, 71.40, 62.08, 21.17, 20.62, 20.57; HRMS (ESI+) *m/z* calcd for C~16~H~21~O~6~S \[M+H\] 341.1059, found 341.1075.

**(2*R*,3*S*,4*S*,5*S*)-2-(Azidomethyl)-5-(*p*-tolylthio)tetrahydrofuran-3,4-diyl diacetate (13)**: To a stirred solution of **12** (17.9 g, 52.7 mmol) and PPh~3~ (27.6 g, 105.1 mmol) in dry toluene (100 mL) were added HN~3~ (1.0 M in toluene, 262.9 mL, 262.9 mmol) and DIAD (20.7 mL, 105.1 mmol). The reaction mixture was stirred for 8 h at rt, and concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 80:20 to 70:30) to afford **13** (19.0 g, 52.0 mmol, 99%): TLC (hexanes/EtOAc 75:25) *R~f~* = 0.40; \[α\]^21^~D~ −0.899 (*c* = 3.93, CHCl~3~); IR (thin film) ν~max~ = 3023, 2924, 2101, 1746, 1493, 1436, 1372, 1233, 1217, 1094, 1064, 1044, 1016, 965, 899, 810 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.43 (d, *J* = 8.1 Hz, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 5.27 (d, *J* = 5.2 Hz, 1H), 5.19 (t, *J* = 5.3 Hz, 1H), 5.11 (t, *J* = 5.2 Hz, 1H), 4.15 (q, *J* = 5.0 Hz, 1H), 3.42 (d, *J* = 1.2 Hz, 1H), 3.41 (d, *J* = 2.2 Hz, 1H), 2.34 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 169.63, 169.35, 138.74, 133.86 (2C), 129.81 (2C), 127.60, 88.27, 80.97, 73.74, 71.73, 52.46, 21.14, 20.50, 20.49; HRMS (ESI+) *m*/*z* calcd for C~16~H~20~N~3~O~5~S \[M+H\] 366.1124, found: 366.1133.

**(2*R*,3*R*,4*S*,5*S*)-2-(Azidomethyl)-5-(*p*-tolylthio)tetrahydrofuran-3,4-diol (13)**: To a stirred solution of **13** (19.0 g, 52.0 mmol) in MeOH (200 mL) was added K~2~CO~3~ (10.0 g, 72.5 mmol). After being stirred for 30 min, the reaction mixture was filtered and concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 70:30 to 50:50) to afford **14** (12.9 g, 45.9 mmol, 88%): TLC (hexanes/EtOAc 33:67) *R~f~* = 0.60; \[α\]^21^~D~ −0.152 (*c* = 0.34, CHCl~3~); IR (thin film) ν~max~ = 3385 (br), 2923, 2103, 1493, 1437, 1399, 1286, 1117, 1065, 1042, 1017, 809 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.42 (d, *J* = 7.7 Hz, 2H), 7.14 (d, *J* = 7.8 Hz, 2H), 5.19 (d, *J* = 4.7 Hz, 1H), 4.11 (t, *J* = 4.4 Hz, 1H), 4.04 (d, *J* = 3.7 Hz, 2H), 3.49 (dd, *J* = 13.0, 2.9 Hz, 1H), 3.42 (dd, *J* = 13.0, 4.2 Hz, 1H), 2.57 (brs, 2H), 2.34 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 138.34, 133.17 (2C), 129.82 (2C), 128.68, 90.76, 82.62, 74.88, 72.24, 52.68, 21.15; HRMS (ESI+) *m*/*z* calcd for C~12~H~16~N~3~O~3~S \[M+H\] 282.0912, found: 282.0928.

**(2*R*,5*S*)-2-(Azidomethyl)-5-(*p*-tolylthio)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (4)**: To a stirred solution of **14** (12.9 g, 45.9 mmol) and **15** (34.7 g, 114.8 mmol) in CH~2~Cl~2~ (231 mL) were added DMAP (1.12 g, 9.17 mmol) and DIC (18.0 mL, 114.8 mmol) at 0 °C. The reaction mixture was stirred for 16 h at rt and concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 95:5) to afford **4** (35.1 g, 41.2 mmol, 90%): TLC (hexanes/EtOAc 90:10) *R~f~* = 0.60; \[α\]^21^~D~ −0.293 (*c* = 1.39, CHCl~3~); IR (thin film) ν~max~ = 2792, 2892, 2866, 2102, 1745, 1464, 1390, 1367, 1282, 1254, 1219, 1190, 1100, 1071, 1054, 1013, 998, 882, 809, 772, 742, 681 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.43 (d, *J* = 8.1 Hz, 2H), 7.14 (d, *J* = 7.9 Hz, 2H), 5.26 (d, *J* = 5.3 Hz, 1H), 5.18 (t, *J* = 5.3 Hz, 1H), 5.11 (t, *J* = 5.0 Hz, 1H), 4.13 (q, *J* = 4.7 Hz, 1H), 3.76 (dt, *J* = 10.6, 6.9 Hz, 4H), 3.42 (d, *J* = 4.7 Hz, 2H), 2.34 (s, 3H), 2.31 (d, *J* = 10.6 Hz, 2H), 2.26 (d, *J* = 4.9 Hz, 2H), 1.61 (dtd, *J* = 17.4, 6.9, 2.1 Hz, 4H), 1.08--1.00 (m, 54H); ^13^C NMR (101 MHz, CDCl~3~) δ 170.91, 170.54, 138.67, 133.89 (2C), 129.81 (2C), 127.88, 88.58, 81.48, 73.52, 71.70, 60.02, 59.97, 52.70, 46.15, 46.03, 44.64, 44.55, 32.68, 32.60, 27.51, 27.47, 27.38, 21.17, 18.06 (6C), 18.05 (6C), 11.93 (3C), 11.92 (3C); HRMS (ESI+) *m*/*z* calcd for C~44~H~79~N~3~NaO~7~SSi~2~ \[M+Na\] 872.5075, found: 872.5088.

**3-(((2,6-Dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-1-((3a*R*,4*R*,6*R*,6a*R*)-6-((*S*)-1-hydroxy-5-phenylpent-2-yn-1-yl)-2,2-dimethyltetrahydrofuro\[3,4-*d*\]\[1,3\]dioxol-4-yl)pyrimidine-2,4(1*H*,3*H*)-dione (3)**: Title compound was synthesized according to the reported procedure \[[@bib0005]\]: TLC (hexanes/EtOAc 50:50) *R~f~* = 0.30; \[α\]^22^~D~ −0.116 (*c* = 2.17, CHCl~3~); IR (thin film) ν~max~ = 3387 (br), 2981, 2937, 1664, 1454, 1276, 1065, 1039, 856, 733, 698 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.53 (ddd, *J* = 20.4, 8.5, 0.7 Hz, 1H), 7.35--7.27 (m, 4H), 7.24--7.15 (m, 4H), 6.85 (d, *J* = 5.1 Hz, 2H), 6.51 (d, *J* = 5.4 Hz, 1H), 5.68 (dd, *J* = 8.1, 4.1 Hz, 1H), 5.60--5.50 (m, 3H), 4.89--4.78 (m, 2H), 4.57 (ddt, *J* = 12.0, 4.3, 2.0 Hz, 1H), 4.24 (dd, *J* = 4.4, 3.1 Hz, 1H), 3.78 (d, *J* = 3.3 Hz, 3H), 2.83 (t, *J* = 7.5 Hz, 2H), 2.53 (td, *J* = 7.4, 2.0 Hz, 2H), 1.57 (s, 3H), 1.36 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 162.11, 162.08, 159.5, 150.87, 150.85, 141.1, 140.8, 140.30, 140.27, 136.9, 135.4, 135.3, 133.99, 133.95, 133.8, 133.6, 131.2, 129.4, 129.3, 128.41, 128.39, 126.4, 126.21, 126.18, 125.5, 125.4, 115.34, 115.32, 114.3, 114.2, 101.8, 101.7, 96.7, 96.4, 89.23, 89.19, 86.8, 86.7, 84.1, 84.0, 80.9, 69.5, 63.02, 62.99, 55.7, 34.72, 34.70, 27.2, 25.3, 20.87, 20.85; HRMS (ESI+) *m*/*z* calcd for C~37~H~34~N~2~O~8~NaCl~4~ \[M+Na\] 797.0967, found: 797.0994.

**(2*R*,3*R*,4*R*,5*R*)-2-(Azidomethyl)-5-(((1*S*)-1-((3a*R*,4*R*,6*R*,6a*R*)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,2-dimethyltetrahydrofuro\[3,4-*d*\]\[1,3\]dioxol-4-yl)-5-phenylpent-2-yn-1-yl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (5)**. To a stirred suspension of **3** (5 g, 6.44 mmol), **4** (6.57 g, 7.73 mmol), MS3A (7.56 g) and SrCO~3~ (4.75 g, 32.2 mmol) in CH~2~Cl~2~ (260 mL) were added AgBF~4~ (0.63 g, 3.22 mmol) and NIS (1.88 g, 8.37 mmol) at 0 °C. After 24 h, the reaction mixture was added Et~3~N (2 mL) and passed through a silica gel pad (hexanes/EtOAc 1:1). The combined organic phase was concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 90:10 to 80:20 to 70:30) to afford 5 (9.19 g, 6.12 mmol, 95%): TLC (hexanes/EtOAc 67:33) *R~f~* = 0.70; \[α\]^21^~D~ +0.100 (*c* = 2.09, CHCl~3~); IR (thin film) ν~max~ = 2942, 2866, 2102, 1743, 1724, 1675, 1456, 1278, 1218, 1099, 1070, 882, 772 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.54 (dd, *J* = 23.1, 8.5 Hz, 1H), 7.32--7.27 (m, 4H), 7.24--7.16 (m, 4H), 6.84 (d, *J* = 7.3 Hz, 2H), 6.51 (d, *J* = 3.7 Hz, 1H), 5.71--5.64 (m, 2H), 5.60--5.49 (m, 2H), 5.20--5.16 (m, 3H), 4.79 (ddd, *J* = 7.5, 6.5, 3.1 Hz, 1H), 4.64 (td, *J* = 5.9, 2.6 Hz, 1H), 4.57 (ddt, *J* = 11.4, 6.3, 1.9 Hz, 1H), 4.28 (dt, *J* = 6.2, 2.8 Hz, 1H), 4.19 (tt, *J* = 6.1, 3.0 Hz, 1H), 3.79--3.72 (m, 7H), 3.50 (ddd, *J* = 13.0, 7.6, 3.3 Hz, 1H), 3.35 (dd, *J* = 13.0, 3.4 Hz, 1H), 2.83 (t, *J* = 7.4 Hz, 2H), 2.55 (td, *J* = 7.4, 1.8 Hz, 2H), 2.29 (t, *J* = 1.6 Hz, 2H), 2.24 (dd, *J* = 5.1, 2.1 Hz, 2H), 1.62--1.55 (m, 7H), 1.36 (d, *J* = 2.0 Hz, 3H), 1.08--1.00 (m, 54H); ^13^C NMR (101 MHz, CDCl~3~) δ 175.6, 171.0, 170.9, 170.71, 170.70, 170.6, 162.2, 162.1, 159.5, 150.8, 150.7, 140.4, 140.19, 140.15, 140.13, 136.92, 136.91, 135.4, 135.3, 133.9, 133.8, 133.7, 131.2, 129.4, 129.3, 128.5 (2C), 128.4 (2C), 126.5, 126.4, 126.2, 126.1, 125.6, 125.5, 115.29, 115.25, 114.23, 114.22, 104.61, 104.55, 101.83, 101.82, 88.8, 88.2, 84.44, 84.35, 83.9, 81.4, 81.3, 80.6, 79.9, 76.5, 75.9, 75.8, 74.1, 71.8, 71.7, 71.4, 70.7, 69.6, 69.5, 68.9, 68.8, 59.97, 59.96, 55.7, 46.2, 46.0, 44.7, 44.6, 34.7, 34.51, 34.49, 32.7, 32.61, 32.57, 28.0, 27.38, 27.35, 27.3, 27.1, 25.34, 25.27, 20.9, 18.1 (12C), 11.9 (6C); HRMS (ESI+) *m*/*z* calcd for C~74~H~106~Cl~4~N~5~O~15~Si~2~ \[M+H\] 1500.5978, found: 1500.5992.

(**2*R*,3*R*,4*R*,5*R*)-2-(Aminomethyl)-5-(((1*S*)-1-((3a*R*,4*R*,6*R*,6a*R*)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,2-dimethyltetrahydrofuro\[3,4-*d*\]\[1,3\]dioxol-4-yl)-5-phenylpent-2-yn-1-yl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (22)**: A suspended solution of **5** (7.03 g, 4.68 mmol), NH~4~Cl (7.50 g, 140.3 mmol) and Zn (9.17 g, 140.3 mmol) in EtOH/H~2~O (9:1, 50 mL) was stirred at 80 °C for 12 h and cooled to rt. The precipitates were filtered and the combined organic solution was concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 50:50 to CHCl~3~/MeOH 96:4) to afford the primary amine **22** (5.80 g, 3.93 mmol, 84%): TLC (CHCl~3~/MeOH 90:10) *R~f~* = 0.60; \[α\]^21^~D~ −0.013 (*c* = 1.35, CHCl~3~); IR (thin film) ν~max~ = 2941, 2866, 1742, 1721, 1675, 1600, 1556, 1461, 1382, 1278, 1215, 1099, 1070, 1050, 999, 882 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.64 (s, 1H), 7.50 (dd, *J* = 31.4, 8.4 Hz, 1H), 7.33--7.30 (m, 2H), 7.28 (d, *J* = 7.5 Hz, 3H), 7.24--7.15 (m, 5H), 6.85 (d, *J* = 9.5 Hz, 2H), 6.49 (d, *J* = 6.1 Hz, 1H), 5.75 (dd, *J* = 8.5, 1.9 Hz, 1H), 5.72--5.66 (m, 1H), 5.59--5.46 (m, 2H), 5.30 (d, *J* = 5.3 Hz, 1H), 5.22--5.13 (m, 2H), 4.82 (dt, *J* = 6.3, 3.1 Hz, 1H), 4.78 (d, *J* = 7.0 Hz, 1H), 4.65 (dd, *J* = 14.5, 7.6 Hz, 1H), 4.28 (dt, *J* = 7.4, 3.5 Hz, 1H), 4.17 (quin, *J* = 3.9 Hz, 1H), 3.87 (t, *J* = 5.8 Hz, 1H), 3.75 (dt, *J* = 15.3, 6.3 Hz, 6H), 3.14 (d, *J* = 13.6 Hz, 1H), 2.94--2.86 (m, 1H), 2.83 (t, *J* = 7.4 Hz, 2H), 2.55 (td, *J* = 7.2, 2.0 Hz, 2H), 2.35 (s, 1H), 2.30 (s, 2H), 2.25 (s, 2H), 2.23--2.17 (m, 1H), 1.70 (t, *J* = 5.9 Hz, 1H), 1.63--1.51 (m, 4H), 1.35 (d, *J* = 5.1 Hz, 2H), 1.25 (s, 1H), 1.12--0.95 (m, 51H); ^13^C NMR (101 MHz, CDCl~3~) δ 173.46, 171.73, 171.39, 170.66, 162.24, 159.45, 150.84, 140.16, 136.82, 135.21, 135.04, 134.04, 133.95, 133.75, 131.18, 131.16, 131.14, 129.40, 129.35, 128.52, 128.43 (2C), 128.40 (2C), 128.37, 126.42, 126.29, 126.16, 125.40, 125.26, 115.30, 115.24, 114.01, 101.82, 89.55, 84.49, 74.87, 70.13, 60.70, 59.93, 55.69, 47.00, 46.16, 45.95, 44.74, 44.64, 42.72, 34.53, 34.51, 32.62, 32.58, 32.33, 29.69, 28.47, 27.38, 27.34, 27.29, 27.03, 25.21, 25.19, 20.92, 18.04 (12C), 17.92, 11.87 (6C), 11.78; HRMS (ESI+) *m*/*z* calcd for C~74~H~108~Cl~4~N~3~O~15~Si~2~ \[M+H\] 1474.6073, found: 1475.6091.

**(2*R*,3*R*,4*R*,5*R*)-2-(((*tert*-Butoxycarbonyl)amino)methyl)-5-(((1*S*,*Z*)-1-((3a*R*,4*R*,6*R*,6a*R*)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,2-dimethyltetrahydrofuro\[3,4-*d*\]\[1,3\]dioxol-4-yl)-5-phenylpent-2-en-1-yl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (6)**: To a stirred solution of **22** (5.80 g, 3.93 mmol) and quinoline (10 mL) in THF-MeOH (1:1, 200 mL) was added Lindlar catalyst (2.90 g). H~2~ gas was introduced and the reaction mixture was stirred under H~2~ atmosphere (1000 psi). After being stirred for 20 h, the reaction mixture was added Lindlar catalyst (2.90 g). The reaction mixture was stirred for 20 h under H~2~ atmosphere (1000 psi) at rt. The solution was filtered through Celite, concentrated *in vacuo*. The crude mixture was used for the next reaction without purification. To a stirred solution of the crude mixture in CH~2~Cl~2~ (40 mL) was Boc~2~O (1.29 g, 5.89 mmol). After being stirred for 12 h at rt, the reaction mixture was quenched with 1*N* HCl and extracted with EtOAc. The combined organic solution was washed with saturated aq. NaHCO~3~, dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude mixture was passed through a silica gel pad (hexanes/EtOAc 80:20 to 70:30). to afford 6 (4.71 g, 2.99 mmol, 76%): TLC (hexanes/EtOAc 75:25) *R~f~* = 0.40; \[α\]^21^~D~ −0.015 (*c* = 0.86, CHCl~3~); IR (thin film) ν~max~ = 3403 (br), 2957, 2941, 2866, 1720, 1675, 1600, 1556, 1507, 1456, 1382, 1367, 1278, 1247, 1218, 1161, 1100, 1071, 1049, 1013, 999, 882 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.54 (dd, *J* = 8.4, 6.7 Hz, 1H), 7.35 (d, *J* = 8.2 Hz, 1H), 7.30 (t, *J* = 2.1 Hz, 2H), 7.25--7.21 (m, 2H), 7.21--7.12 (m, 5H), 6.82 (d, *J* = 10.7 Hz, 2H), 6.51 (d, *J* = 13.6 Hz, 1H), 5.84--5.74 (m, 2H), 5.72 (d, *J* = 8.1 Hz, 1H), 5.62--5.50 (m, 2H), 5.47 (t, *J* = 8.0 Hz, 1H), 5.14 (t, *J* = 4.2 Hz, 1H), 5.07--4.97 (m, 2H), 4.90 (s, 1H), 4.75 (ddd, *J* = 24.4, 6.4, 2.0 Hz, 1H), 4.58--4.45 (m, 2H), 4.19 (dt, *J* = 8.4, 4.2 Hz, 1H), 4.01 (dt, *J* = 6.6, 4.3 Hz, 1H), 3.76 (d, *J* = 5.1 Hz, 4H), 3.75--3.70 (m, 4H), 3.32 (d, *J* = 5.0 Hz, 2H), 2.79--2.58 (m, 2H), 2.57--2.41 (m, 2H), 2.36--2.28 (m, 1H), 2.26--2.19 (m, 5H), 1.66--1.52 (m, 4H), 1.41 (s, 6H), 1.33 (d, *J* = 4.9 Hz, 2H), 1.05 (q, *J* = 2.7 Hz, 51H), 0.99 (dd, *J* = 9.6, 4.0 Hz, 4H); ^13^C NMR (101 MHz, CDCl~3~) δ 170.87, 159.38, 155.94, 150.85, 141.06, 136.87, 136.80, 135.57, 135.31, 135.27, 133.86, 133.66, 133.56, 131.23, 131.20, 129.29, 129.27, 128.52, 128.51, 128.37 (2C), 126.16, 126.15, 126.06, 126.03, 125.99, 125.64, 125.52, 125.46, 125.43, 115.24, 115.23, 114.17, 114.11, 84.61, 81.15, 81.03, 79.30, 79.25, 74.72, 74.29, 70.50, 69.81, 59.95, 59.91, 55.66, 55.65, 46.18, 46.17, 45.92, 44.80, 44.79, 41.64, 35.37, 35.34, 32.56, 32.55, 32.52, 32.50, 29.70, 28.34, 27.27, 27.24, 27.22, 27.10, 27.08, 25.25, 18.05 (12C), 17.88, 11.88 (6C), 11.74; HRMS (ESI+) *m*/*z* calcd for C~79~H~118~Cl~4~N~3~O~17~Si~2~ \[M+H\] 1576.6754, found: 1576.6771.

**(4-(4-(4-(Trifluoromethoxy)phenoxy)piperidin-1-yl)phenyl)methanamine (20)**: The title compound was synthesized according to the reported procedure \[[@bib0025]\]: ^1^H NMR (400 MHz, CDCl~3~) δ 7.21 (d, *J* = 8.2 Hz, 2H), 7.14 (d, *J* = 8.6 Hz, 2H), 6.97--6.87 (m, 4H), 4.43 (tt, *J* = 7.7, 3.8 Hz, 1H), 3.79 (s, 2H), 3.49 (ddd, *J* = 11.7, 7.2, 3.7 Hz, 2H), 3.09 (ddd, *J* = 12.2, 8.2, 3.6 Hz, 2H), 2.15--2.06 (m, 2H), 1.98--1.88 (m, 2H); ^13^C NMR (101 MHz, CDCl~3~) δ 155.8, 150.2, 142.8, 134.6, 128.0 (2C), 122.5 (2C), 116.83 (2C), 116.76 (2C), 72.9, 46.9 (2C), 45.9, 30.4 (2C); HRMS (ESI+) *m*/*z* calcd for C~19~H~22~F~3~N~2~O~2~ \[M+H\] 367.1633, found 367.1628.

***tert*-Butyl (4-oxo-4-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)amino)butyl)carbamate (21)**: To a stirred solution of 4-aminobutyric acid (2.50 g, 24.0 mmol) and NaHCO~3~ (6.00 g, 72.0 mmol) in THF-H~2~O (1:1, 24 mL) was added Boc~2~O (5.76 g, 26.4 mmol). After being stirred for 8 h at rt, the reaction mixture was quenched with 1*N* HCl and extracted with CHCl~3~. The combined organic solution was dried over Na~2~SO~4~ and concentrated *in vacuo*. To a stirred solution of the crude mixture, **20** (4.45 g, 12.14 mmol), NaHCO~3~ (5.10 g, 60.7 mmol) and Glyceroacetonide-Oxyma (5.54 g, 24.3 mmol) in DMF-H~2~O (9:1, 60 mL), was added EDCI (4.65 g, 24.3 mmol). After being stirred for 13 h at rt, the reaction mixture was quenched with H~2~O and extracted with EtOAc. The combined organic solution was washed with 1*N* HCl (aq.), saturated NaHCO~3~ (aq.), dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude mixture was purified by silica gel column chromatography (hexanes/EtOAc 33:67 to 20:80) to afford **21** (5.35 g, 9.71 mmol, 80%) \[[@bib0020]\]: TLC (hexanes/EtOAc 20:80) *R~f~* = 0.30; IR (thin film) ν~max~ = 3303 (br), 2931, 1692, 1637, 1613, 1542, 1504, 1465, 1366, 1264, 1238, 1219, 1193, 1159, 1120, 1111, 1036, 918, 841, 827, 772 cm^−1^; ^1^H NMR (400 MHz, Chloroform-*d*) δ 7.19 (dd, *J* = 8.4, 4.7 Hz, 2H), 7.14 (d, *J* = 8.8 Hz, 2H), 6.91 (dd, *J* = 9.1, 1.1 Hz, 4H), 6.22 (brs, 1H), 4.77 (brs, 1H), 4.72 (brs, 1H), 4.44 (tt, *J* = 7.2, 3.5 Hz, 1H), 4.35 (d, *J* = 5.6 Hz, 1H), 4.29 (d, *J* = 5.5 Hz, 1H), 3.48 (ddt, *J* = 11.6, 7.6, 3.8 Hz, 2H), 3.20--3.05 (m, 4H), 2.22 (t, *J* = 7.1 Hz, 2H), 2.18--2.07 (m, 2H), 1.98--1.89 (m, 2H), 1.81 (quin, *J* = 6.9 Hz, 2H), 1.43 (s, 9H); ^13^C NMR (101 MHz, CDCl~3~) δ 172.31, 157.99, 156.40, 155.72, 155.70, 142.76, 128.90 (2C), 128.56 (2C), 122.52 (3C), 116.76 (3C), 79.32, 72.55, 46.87, 44.10, 43.12, 39.76, 33.69, 30.15, 28.38 (3C), 26.35; HRMS (ESI+) *m*/*z* calcd for C~28~H~37~F~3~N~3~O~5~ \[M+H\] 552.2685, found: 552.2701.

**4-Amino-*N*-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)butanamide (8)**: To a stirred solution of **22** (3.81 g, 6.99 mmol) in CH~2~Cl~2~ (10 mL) was added TFA (5 mL). The reaction mixture was stirred for 3 h at rt, and all volatile were evaporated *in vacuo*. The residue was neutralized with aq. NaHCO~3~ extracted with CHCl~3~. The combined organic extracts were dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude mixture of **8** was used for next reaction without purification.

**(2*R*,3*R*,4*R*,5*S*)-2-(((*tert*-Butoxycarbonyl)amino)methyl)-5-(((1*S*)-1-((3a*R*,4*R*,6*R*,6a*R*)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,2-dimethyltetrahydrofuro\[3,4-*d*\]\[1,3\]dioxol-4-yl)-2,3-dihydroxy-5-phenylpentyl)oxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (23)**: To a stirred solution of **6** (4.71 g, 2.99 mmol) and lepidine (2.37 mL, 17.9 mmol) in t-BuOH/THF/H~2~O (1:1:1, 180 mL) were added K~2~CO~3~ (2.06 g, 14.9 mmol), K~3~Fe(CN)~6~ (4.91 g, 14.9 mmol) and K~2~OsO~4~·2H~2~O (1.10 g, 2.99 mmol) at rt. After being stirred for 12 h, the reaction mixture were added K~2~CO~3~ (2.06 g, 14.9 mmol), K~3~Fe(CN)~6~ (4.91 g, 14.9 mmol) and K~2~OsO~4~·2H~2~O (1.10 g, 2.99 mmol). After 20 h, the reaction mixture was diluted with EtOAc and quenched with saturated aq. Na~2~SO~3~. The heterogeneous mixture was stirred for 30 min, and extracted with EtOAc. The combined organic solution was washed with 1*N* HCl, saturated aq. NaHCO~3~, dried over Na~2~SO~4~, and concentrated *in vacuo*. The crude mixture was passed through a silica gel pad (hexanes/EtOAc 75:25 to 50:50) to afford **23** (3.76 g, 2.33 mmol, 78%) as diastereomeric mixture. This mixture was used for next reaction without further purification. Data for less-polar diastereomer: TLC (hexanes/EtOAc 67:33) *R~f~* = 0.30; \[α\]^22^~D~ 0.210 (*c* = 1.62, CHCl~3~); IR (thin film) ν~max~ = 3444 (br), 2941, 2866, 1741, 1719, 1675, 1600, 1556, 1457, 1382, 1367, 1278, 1249, 1216, 1160, 1098, 1070, 1049, 1013, 998, 882, 867, 754, 681 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.52 (dd, *J* = 8.4, 3.6 Hz, 1H), 7.31 (d, *J* = 2.0 Hz, 2H), 7.30--7.27 (m, 2H), 7.25--7.14 (m, 6H), 6.85 (d, *J* = 3.4 Hz, 2H), 6.50 (d, *J* = 5.9 Hz, 1H), 5.75 (dd, *J* = 17.6, 8.0 Hz, 1H), 5.63 (d, *J* = 22.1 Hz, 1H), 5.58--5.52 (m, 2H), 5.48 (d, *J* = 9.7 Hz, 1H), 5.21 (q, *J* = 7.3, 6.2 Hz, 2H), 5.11 (d, *J* = 6.8 Hz, 1H), 5.01 (dd, *J* = 8.4, 4.7 Hz, 1H), 4.85--4.78 (m, 2H), 4.25 (d, *J* = 5.6 Hz, 1H), 4.16 (dt, *J* = 8.6, 4.4 Hz, 1H), 4.03 (dd, *J* = 14.2, 5.1 Hz, 1H), 3.90 (d, *J* = 1.8 Hz, 1H), 3.78 (d, *J* = 1.8 Hz, 4H), 3.77--3.71 (m, 4H), 3.69--3.62 (m, 2H), 3.39--3.22 (m, 2H), 2.97--2.86 (m, 2H), 2.77--2.66 (m, 2H), 2.34--2.18 (m, 5H), 2.12--2.00 (m, 1H), 1.91--1.67 (m, 2H), 1.64--1.51 (m, 4H), 1.42 (s, 6H), 1.35 (d, *J* = 3.9 Hz, 3H), 1.13--0.99 (m, 41H), 0.99--0.94 (m, 6H), 0.86 (dtd, *J* = 9.1, 6.6, 2.2 Hz, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 170.85, 170.74, 170.70, 170.70, 162.10, 162.09, 159.44, 159.44, 156.05, 150.59, 150.53, 141.92, 141.89, 136.87, 136.84, 135.25, 135.09, 133.96, 133.77, 131.21, 131.17, 129.37, 129.32, 128.43 (2C), 128.38 (2C), 126.22, 126.14, 125.81, 125.36, 125.26, 115.27, 114.97, 80.36, 80.34, 79.85, 79.67, 79.58, 74.64, 74.62, 74.60, 73.82, 73.77, 73.72, 70.31, 70.31, 59.94, 59.90, 55.69, 46.13, 45.92, 44.72, 34.63, 34.50, 32.58, 32.57, 32.55, 32.54, 31.76, 29.69, 29.03, 28.35, 27.28, 27.22, 26.88, 25.32, 25.25, 20.68, 18.04 (1C), 11.88 (3C), 11.86 (3C), 11.43; HRMS (ESI+) *m*/*z* calcd for C~79~H~120~Cl~4~N~3~O~19~Si~2~ \[M+H\] 1610.6809, found: 1610.6827. Data for polar diastereomer: TLC (hexanes/EtOAc 67:33) *R~f~* = 0.20; \[α\]^22^~D~ 0.071 (*c* = 1.08, CHCl~3~); IR (thin film) ν~max~ = 3413 (br), 2941, 2866, 1719, 1675, 1457, 1367, 1278, 1248, 1219, 1160, 1099, 1070, 1049, 882, 772 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.58 (d, *J* = 8.5 Hz, 1H), 7.31--7.29 (m, 2H), 7.28 (s, 2H), 7.24--7.11 (m, 6H), 6.84 (d, *J* = 1.4 Hz, 2H), 6.51 (d, *J* = 6.6 Hz, 1H), 5.90 (dd, *J* = 6.3, 2.7 Hz, 1H), 5.84 (t, *J* = 8.2 Hz, 1H), 5.61--5.41 (m, 2H), 5.23--5.10 (m, 2H), 5.04 (t, *J* = 5.8 Hz, 2H), 4.86--4.77 (m, 1H), 4.68 (ddd, *J* = 21.0, 6.3, 2.8 Hz, 1H), 4.57 (dt, *J* = 10.8, 3.8 Hz, 1H), 4.25--4.14 (m, 1H), 4.06--3.98 (m, 1H), 3.92--3.84 (m, 1H), 3.80--3.71 (m, 6H), 3.47--3.23 (m, 2H), 2.92--2.83 (m, 2H), 2.77--2.66 (m, 2H), 2.31--2.20 (m, 4H), 2.19--2.06 (m, 2H), 1.92--1.66 (m, 3H), 1.63--1.53 (m, 6H), 1.42 (d, *J* = 3.7 Hz, 2H), 1.36 (s, 6H), 1.10--0.94 (m, 50H), 0.91--0.81 (m, 3H); ^13^C NMR (101 MHz, CDCl~3~) δ 171.04, 171.01, 170.93, 170.92, 162.00, 159.38, 150.79, 136.92, 136.91, 135.45, 131.30, 131.28, 129.29, 129.28, 128.46 (2C), 128.42 (2C), 126.09, 125.95, 125.93, 115.24, 81.03, 81.01, 79.95, 79.67, 75.03, 75.00, 74.98, 72.17, 70.38, 70.31, 69.52, 69.49, 59.95, 59.91, 55.69, 55.67, 46.13, 45.93, 44.86, 44.66, 35.27, 35.25, 34.64, 32.63, 32.59, 32.58, 31.95, 28.32, 27.38, 27.37, 27.36, 27.28, 27.27, 27.20, 26.89, 25.26, 18.05 (12C), 11.88 (3C), 11.87 (3C); HRMS (ESI+) *m*/*z* calcd for C~79~H~120~Cl~4~N~3~O~19~Si~2~ \[M+H\] 1610.6809, found: 1610.6831.

**(2*R*,3*R*,4*R*,5*S*)-2-(((*tert*-Butoxycarbonyl)amino)methyl)-5-((1*S*,2*R*)-2-cyano-1-((3a*R*,4*R*,6*R*,6a*R*)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,2-dimethyltetrahydrofuro\[3,4-*d*\]\[1,3\]dioxol-4-yl)-2-((4-oxo-4-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)amino)butyl)amino)ethoxy)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (9)**: To a stirred suspension of **23** (3.76 g, 2.33 mmol) and NaHCO~3~ (0.98 g, 11.6 mmol) in CH~2~Cl~2~ (46.6 mL) was added Pb(OAc)~4~ (2.06 g, 4.66 mmol) at 0 °C. The reaction mixture was stirred for 2 h at 0 °C and quenched with saturated aq. NaHCO~3~, and extracted with EtOAc. The combined organic extracts were dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude mixture of aldehyde **7** was used for the next reaction without purification. To a stirred solution of **7** (3.44 g, 2.33 mmol) and **8** (3.15 g, 6.99 mmol) in CH~2~Cl~2~ (30 mL) was added MS3A (7.5 g) followed by Ti(OiPr)~4~ (6.89 mL, 23.3 mmol). After 6 h, the reaction was added TMSCN (2.91 mL, 23.3 mmol) and stirred for 12 h at rt. After completion, the reaction mixture was quenched with saturated aq. NaHCO~3~, and extracted with EtOAc. The combined organic extracts were dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography (hexanes/EtOAc 80:20 to 60:40) to afford **9*S*** (3.15 g, 1.63 mmol, 70% for 2 steps): TLC (hexanes/EtOAc 50:50) *R~f~* = 0.40; \[α\]^21^~D~ +0.102 (*c* = 0.75, CHCl~3~); IR (thin film) ν~max~ = 3342 (br), 2941, 2866, 1718, 1675, 1505, 1464, 1243, 1164, 1101, 1071, 883, 772, 688 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.49 (dd, *J* = 8.5, 4.3 Hz, 1H), 7.32 (d, *J* = 2.0 Hz, 1H), 7.22--7.11 (m, 7H), 6.94--6.88 (m, 5H), 6.86 (d, *J* = 6.5 Hz, 2H), 6.50 (d, *J* = 8.6 Hz, 1H), 6.25--6.16 (m, 1H), 5.73 (dd, *J* = 22.2, 8.0 Hz, 1H), 5.60 (t, *J* = 8.8 Hz, 1H), 5.56--5.41 (m, 3H), 5.21 (d, *J* = 4.4 Hz, 1H), 5.05--4.98 (m, 2H), 4.94--4.77 (m, 2H), 4.53--4.37 (m, 3H), 4.25--4.16 (m, 2H), 4.05--3.98 (m, 1H), 3.80--3.69 (m, 6H), 3.68--3.63 (m, 1H), 3.56 (dd, *J* = 17.3, 3.4 Hz, 1H), 3.48 (ddt, *J* = 11.6, 7.2, 4.0 Hz, 2H), 3.44--3.29 (m, 1H), 3.08 (dq, *J* = 9.5, 5.3, 4.8 Hz, 2H), 2.95 (dt, *J* = 11.4, 5.5 Hz, 1H), 2.47 (td, *J* = 12.0, 11.4, 5.7 Hz, 1H), 2.36--2.14 (m, 5H), 2.13--2.05 (m, 2H), 1.97--1.85 (m, 3H), 1.84--1.75 (m, 1H), 1.58 (t, *J* = 6.9 Hz, 2H), 1.55--1.50 (m, 4H), 1.40 (s, 9H), 1.33 (d, *J* = 4.8 Hz, 3H), 1.28--1.23 (m, 3H), 1.08--1.02 (m, 42H), 1.01 (s, 6H), 0.94 (d, *J* = 2.1 Hz, 6H); ^13^C NMR (101 MHz, CDCl~3~) δ 172.4, 171.0, 170.9, 159.5, 155.8, 150.9, 150.7, 142.8, 136.9, 136.8, 135.3, 135.1, 134.13, 134.05, 133.86, 133.85, 133.78, 131.2, 131.1, 129.42, 129.37, 129.0, 126.4, 126.2, 125.5, 125.2, 122.5 (2C), 121.8, 119.3, 118.4, 116.8 (2C), 116.6 (2C), 115.4, 115.3, 114.71, 114.66, 106.4, 102.3, 102.2, 84.8, 80.7, 80.6, 79.9, 79.8, 79.3, 76.2, 74.32, 74.30, 72.9, 60.38, 60.35, 60.0, 59.9, 55.72, 55.71, 52.0, 46.6, 46.2, 45.9, 44.84, 44.77, 42.99, 42.96, 42.4, 41.2, 33.53, 33.49, 32.6, 32.5, 30.3, 28.4, 27.3 (2C), 27.17, 27.16, 27.1, 25.4, 18.1 (12C), 14.2, 14.1, 11.91 (3C), 11.90 (3C); HRMS (ESI+) *m*/*z* calcd for C~94~H~135~Cl~4~F~3~N~7~O~20~Si~2~ \[M+H\] 1934.8007, found: 1934.8021.

**(2*S*,3*R*,4*R*,5*R*)-2-((1*S*,2*S*)-3-Amino-1-((3a*R*,4*R*,6*R*,6a*R*)-6-(3-(((2,6-dichloro-4-methoxyphenyl)(2,4-dichlorophenyl)methoxy)methyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-2,2-dimethyltetrahydrofuro\[3,4-*d*\]\[1,3\]dioxol-4-yl)-3-oxo-2-((4-oxo-4-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)amino)butyl)amino)propoxy)-5-(((*tert*-butoxycarbonyl)amino)methyl)tetrahydrofuran-3,4-diyl bis(3,3-dimethyl-5-((triisopropylsilyl)oxy)pentanoate) (10)**: To a stirred solution of **9*S*** (3.15 g, 1.63 mmol) in EtOH/H~2~O (9:1, 10 mL) were added HgCl~2~ (0.89 g, 3.26 mmol) and acetaldoxime (0.99 mL, 16.3 mmol) at rt. After being stirred for 10 h at rt, the reaction mixture was concentrated under reduced pressure. The residue was quenched with saturated aq. NaHCO~3~, extracted with CHCl~3~. The combined organic extracts were dried over Na~2~SO~4~ and concentrated *in vacuo*. The crude product was purified by silica gel column chromatography (CHCl~3~/MeOH 99.5:0.5--99.2:0.8--98.8:1.2) to afford **10** (2.64 g, 1.35 mmol, 83%): TLC (CHCl~3~/MeOH 95:5) *R~f~* = 0.30; \[α\]^21^~D~ +0.144 (*c* = 0.53, CHCl~3~); IR (thin film) ν~max~ = 3335 (br), 2940, 2866, 1719, 1676, 1505, 1464, 1367, 1242, 1162, 1101, 1070, 882, 681 cm^−1^; ^1^H NMR (400 MHz, CDCl~3~) δ 7.53 (dd, *J* = 8.6, 5.1 Hz, 1H), 7.30 (s, 1H), 7.28--7.22 (m, 2H), 7.21--7.12 (m, 6H), 6.91 (d, *J* = 8.5 Hz, 4H), 6.86 (d, *J* = 2.6 Hz, 2H), 6.51 (d, *J* = 8.7 Hz, 1H), 5.94 (brs, 1H), 5.79--5.67 (m, 3H), 5.56--5.47 (m, 2H), 5.17 (brs, 1H), 5.06 (s, 1H), 4.96 (brs, 1H), 4.82--4.73 (m, 2H), 4.43 (tt, *J* = 7.8, 3.8 Hz, 1H), 4.39--4.28 (m, 3H), 4.21 (brs, 1H), 4.13 (brs, 1H), 3.78 (s, 3H), 3.73 (q, *J* = 7.4 Hz, 5H), 3.67 (brs, 1H), 3.48 (ddd, *J* = 11.7, 7.2, 3.7 Hz, 2H), 3.41--3.28 (m, 1H), 3.17 (s, 1H), 3.09 (ddd, *J* = 12.2, 8.2, 3.3 Hz, 2H), 2.80--2.60 (m, 2H), 2.38--2.15 (m, 7H), 2.13--2.05 (m, 2H), 1.93 (ddd, *J* = 12.8, 8.0, 3.7 Hz, 2H), 1.85--1.79 (m, 2H), 1.54 (s, 3H), 1.42 (s, 9H), 1.34 (s, 3H), 1.04 (d, *J* = 2.8 Hz, 42H), 1.01 (s, 6H), 0.96 (s, 6H); ^13^C NMR (101 MHz, CDCl~3~) δ 162.1, 162.0, 159.6, 159.5, 156.2, 155.8, 150.9, 150.4, 142.80, 142.78, 136.88, 136.86, 135.23, 135.21, 133.9, 133.6, 131.33, 131.30, 131.29, 129.40, 129.37, 129.2, 129.1, 129.02, 128.98, 126.24, 126.22, 126.21, 125.40, 125.36, 124.5, 124.4, 123.20, 123.19, 122.5 (2C), 121.8, 120.1, 119.3, 116.8 (2C), 115.4, 80.4, 80.02, 79.99, 79.96, 79.95, 79.92, 79.87, 79.85, 79.83, 74.51, 74.50, 72.7, 70.4, 70.3, 69.5, 60.0, 59.9, 55.73, 55.72, 46.7, 46.19, 46.15, 46.13, 46.11, 46.10, 46.07, 46.0, 44.8, 34.7, 34.5, 32.61, 32.58, 30.2, 29.7, 29.64, 29.60, 28.50, 28.45, 28.42, 28.38, 28.34, 27.25 (2C), 27.19, 27.16, 25.31, 25.29, 25.27, 18.1 (12C), 14.1, 12.2, 11.9 (6C); HRMS (ESI+) *m*/*z* calcd for C~94~H~137~Cl~4~F~3~N~7~O~21~Si~2~ \[M+H\] 1952.8112, found: 1952.8098.

**4-(((2*S*,3*S*)-1-Amino-3-(((2*S*,3*R*,4*S*,5*R*)-5-(aminomethyl)-3,4-dihydroxytetrahydrofuran-2-yl)oxy)-3-((2*S*,5*R*)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-1-oxopropan-2-yl)amino)-*N*-(4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)benzyl)butanamide (1)**: To a stirred solution of **10** (2.64 g, 1.35 mmol) in CH~2~Cl~2~ (15 mL) was added TFA (10 mL). The reaction mixture was stirred for 3 h at rt, and all volatile were evaporated *in vacuo*. To a stirred solution of the crude mixture in H~2~O (5 mL) was added TFA (20 mL). The reaction mixture was stirred for 2 days at rt, and all volatile were evaporated *in vacuo*. The crude mixture was purified by DOWEX (50W x 4) ion exchange resin. The resin was washed with MeOH/H~2~O (4:1) and MeOH. The crude product (TFA salt) was dissolved in MeOH (10 mL) and absorbed on DOWEX (50W x 4): the crude 1 was not detected by TLC (CHCl~3~/MeOH/H~2~O/50% aqueous ammonia 56:42:7:3). The resins were washed with MeOH and eluted with MeOH/50% aqueous ammonia (10:1). The eluate was concentrated under reduced pressure and the resultant aqueous solution was lyophilized. The resulted mixture was purified by C18 reverse-phase HPLC \[column: HYPERSIL GOLD™ (175 Å, 12 μm, 150 × 20 mm), solvents: 80:20 MeOH:0.05M NH~4~HCO~3~ in H~2~O, flow rate: 6.0 mL/min, UV: 254 nm, retention time: 14 min\] to afford 1 (1.05 g, 1.19 mmol, 88%): TLC (*n*-butanol/ethanol/CHCl~3~/28% aqueous ammonia 4:7:2:7) *R~f~* = 0.50; \[α\]^21^~D~ +0.375 (*c* = 0.30, methanol); IR (thin film) ν~max~ = 3352 (br), 2932, 1677, 1505, 1243, 1201, 1136, 801, 722 cm^−1^; ^1^H NMR (400 MHz, CD~3~OD) δ 7.78 (d, *J* = 8.1 Hz, 1H), 7.18 (dd, *J* = 9.0, 3.5 Hz, 4H), 7.00 (dd, *J* = 16.0, 8.6 Hz, 4H), 5.77 (d, *J* = 2.9 Hz, 1H), 5.73 (d, *J* = 8.1 Hz, 1H), 5.14 (s, 1H), 4.57--4.50 (m, 1H), 4.28 (s, 2H), 4.22--4.13 (m, 3H), 4.10 (dd, *J* = 8.6, 4.4 Hz, 1H), 4.07--3.98 (m, 2H), 3.52--3.46 (m, 3H), 3.44 (d, *J* = 8.8 Hz, 1H), 3.17 (d, *J* = 13.0 Hz, 1H), 3.14--3.02 (m, 3H), 2.60 (ddq, *J* = 18.4, 11.8, 6.9 Hz, 2H), 2.29 (td, *J* = 7.3, 2.8 Hz, 2H), 2.12 (dd, *J* = 14.5, 5.6 Hz, 2H), 1.93--1.73 (m, 4H), 1.39--1.25 (m, 2H); ^13^C NMR (101 MHz, CD~3~OD) δ 175.6, 166.2, 157.6, 152.0, 142.6, 131.2, 129.6 (2C), 123.6 (2C), 118.11 (2C), 118.07 (2C), 110.5, 102.7, 92.3, 85.3, 81.4, 80.4, 76.5, 75.1, 74.1 (2C), 73.0, 71.3, 64.4, 43.7, 43.6, 34.7, 31.5, 26.9; HRMS (ESI+) *m*/*z* calcd for C~39~H~51~F~3~N~7~O~13~ \[M+H\] 882.3497, found: 882.3512 ([Fig. 1](#fig0010){ref-type="fig"}).Fig. 1HPLC analysis of **1**.Area % purity: 96.8%.Conditions: column: Phenomenex Kinetex 5 μm XB-C18 100 Å 250 × 4.60 mm column, solvents: 85:15 MeOH:0.05M NH~4~HCO~3~ in water, UV: 254 nm, flow rate: 0.5 mL/min.Fig. 1

### Preparation of HCl salt of **1** {#sec0020}

To a stirred solution of **1** (1.05 g, 1.19 mmol) in MeOH (50 mL) was added ice cold 1*N* HCl (23.8 mL, 23.8 mmol) dropwise. After being stirred for 1 h at rt, the solution was concentrated under reduced pressure and the resultant aqueous solution was lyophilized to give **1**•**HCl** salt ([Fig. 2](#fig0015){ref-type="fig"}).Fig. 2Water solubility of **1•HCl** in saline.Fig. 2

### Determination of solubility of **1**•**HCl** in 0.9% NaCl (saline) {#sec0025}

A suspension of **1**•**HCl** (4.0 mg) in 0.9% NaCl (30 μL) was stirred for 24 h, and the precipitate was separated by centrifugation at 10,000 × *g* for 5 min. The upper solution (1 μL) was analyzed *via* C18 reverse-phase HPLC \[column: Kinetex (100 Å, 5 μm, 250 × 4.60 mm), solvents: 70:30 MeOH: 0.05 M NH~4~HCO~3~ aq., flow rate: 0.5 mL/min, UV: 254 nm, retention time: 12.0 min\]. The area of the peak for **1** was quantified. The concentrations were determined *via* the HPLC intensity-concentration curves \[[@bib0030], [@bib0035], [@bib0040]\].

### Determination of solubility of **1**•**HCl** in PBS (pH7.4) buffer {#sec0030}

A suspension of **1**•**HCl** (3.8 mg) in phosphate buffered saline (pH 7.4, 30 μL) was stirred for 24 h, and the precipitate was separated by centrifugation at 10,000 × *g* for 5 min. The upper solution (1 μL) was analyzed *via* C18 reverse-phase HPLC \[column: Kinetex (100 Å, 5 μm, 250 × 4.60 mm), solvents: 70:30 MeOH:0.05 M NH~4~HCO~3~ aq., flow rate: 0.5 mL/min, UV: 254 nm, retention time: 12.0 min\]. The area of the peak for **1** was quantified. The concentrations were determined *via* the HPLC intensity-concentration curves \[[@bib0030], [@bib0035], [@bib0040]\] ([Fig. 3](#fig0020){ref-type="fig"}).Fig. 3Water solubility of **1•HCl** in PBS (pH7.4).Fig. 3

Microsomal stability {#sec0035}
--------------------

Pooled Sprague-Dawley rat liver microsomes were purchased from Corning Life Sciences (Oneonta, NY, USA). Microsomes (20 mg/mL) were thawed on ice and diluted with PBS, potassium phosphate buffer (100 mM, pH: 7.4) at a 1:8 ratio in 1.5 mL Eppendorf tubes. Stock solutions of **1**•**HCl** and verapamil (positive control) were made by diluting 10 mg/mL solutions. From the drug stock solution, 10 μL was diluted with 390 μL of buffer (0.1 mg/400 μL). The diluted microsomes (390 μL) were reacted with 10 μL of the diluted drug solution and allowed to equilibrate for 5 min while shaking at 440 rpm. NADPH (10 mg/200 μL; 1000× drug concentration) was used as a co-factor for this reaction, and 100 μL was added to the solution after equilibration. Ice cold methanol (200 μL) was used to quench the reaction mixture (50 μL aliquots) at 0, 5, 10, 20, 30, 45 and 60 min. The samples containing methanol was lyophilized to remove all volatiles. The residue was dissolved in 1*N* HCl aq. (10 μL) and MeOH (40 μL). The resulting solution (20 μL) was injected to LC--MS. MS solvent 90:10 acetonitrile/0.05% formic acid in water. Flow rate: 0.5 mL/min ([Fig. 4](#fig0025){ref-type="fig"}).Fig. 4Microsomal stability of **1**.Fig. 4

DPAGT1 assay {#sec0040}
------------

The enzymatic substrate, UDP-Glucosamine-C~6~-FITC was chemically synthesized according to the reported procedures \[[@bib0045]\]. DPAGT1 was expressed in suspended Expi293 cells for 36 h. The cells were lysed by drawing through a 26 g needle (10 times) and membrane protein was extracted using buffer containing 1% DM (decyl β-[d]{.smallcaps}-maltopyranoside) detergent. DPAGT1 was purified using HA (hemagglutinin)-agarose resin and a superdex 200 size exclusion column ([Fig. 5](#fig0030){ref-type="fig"}).Fig. 5DPAGT1-catalyzed reactions.Fig. 5

UDP-Glucosamine-C~6~-FITC (2 mM stock solution, 0.56 μL), MgCl~2~ (0.5 M, 4 μL), β-mercaptoethanol (50 mM, 5 μL), CHAPS (20%, 2.5 μL), Tris buffer (pH 8.0, 50 mM), C~55~-dolichyl phosphate (4 mM, 1.68 μL), and **1•HCl** (0--50 μg/mL in Tris buffer) were place in a 500 μL Eppendorf tube. To a stirred reaction mixture, DPAGT1 solution (10 μL) was added (total volume of reaction mixture: 50 μL adjust with Tris buffer). The reaction mixture was incubated for 4 h at 37 °C and quenched with *n*-butanol (150 μL). Two phases were mixed *via* vortex and centrifuged at 10,000 × *g* for 3 min. The upper organic phase was assayed *via* reverse-phase HPLC. The organic phase (30 μL) was injected into HPLC (solvent: gradient elution of 85:15--95:5 MeOH/0.05 M aq. NH~4~HCO~3~ over 20 min; UV: 485 nm; flow rate: 0.5 mL/min; column: Kinetex 5 μm C8, 100 Å, 150 × 4.60 mm), and the area of the peak for C~55~-P-P-glucosamine-C~6~-FITC was quantified to obtain the IC~50~ value. The IC~50~ values were calculated from plots of the percentage product inhibition *versus* the inhibitor concentration ([Fig. 6](#fig0035){ref-type="fig"}).Fig. 6IC~50~ curve for APPB **(1)**.Fig. 6

Appendix A. Supplementary data {#sec0050}
==============================

The following is Supplementary data to this article:
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